Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)

Study Overview
=================
Brief Summary
-----------------
The primary objective is to evaluate the safety of nusinersen sodium injection in the postmarketing setting in Korea. The secondary objective is to evaluate the effectiveness of nusinersen sodium injection in the postmarketing setting in Korea.

Official Title
-----------------
A Multicenter, Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) When Used in Routine Medical Practice in Korea

Conditions
-----------------
Muscular Atrophy, Spinal

Intervention / Treatment
-----------------
* Drug: Nusinersen Sodium Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Currently receiving or about to initiate treatment with commercial Spinraza in the postmarketing setting Genetic documentation of 5q-linked SMA Key Exclusion Criteria: Hypersensitivity to the active substance or any of the excipients of Spinraza Ongoing participation or participation within 6 months or 5 half-lives of the agent (whichever is longer) of enrollment in other interventional clinical trials for the treatment of SMA Inability to comply with study requirements NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All Participants<br>Participants who were prescribed with nusinersen sodium injection in Korea according to local marketing authorization. | Drug: Nusinersen Sodium Injection<br>* Administered as specified in the treatment arm.<br>* Other names: Spinraza;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event. | Up to End of Treatment (2 Years) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Hammersmith Infant Neurological Examination (HINE) Section 2 Scores | Section 2 of the HINE is used to assess motor milestones of the participants. It is composed of 8 motor milestone categories: voluntary grasp, ability to kick in supine position, head control, rolling, sitting, crawling, standing, and walking. | Baseline, Day 63 and Approximately Every 4 Months Up to End of Treatment (2 years) | 
| Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) | The HFMSE is a tool used to assess motor function in children with SMA. The original 20 item Hammersmith Functional Motor Scale (HFMS) was expanded to include 13 additional items to improve sensitivity for the higher functioning ambulant population. Participants are asked to complete a specific movement and are then graded on the quality and execution of that movement. Higher scores indicate higher levels of motor ability where 0=unable, 1=performed with some assistance, and 2=unaided. The overall score is the sum of the scores for all activities. | Baseline, Day 63 and Approximately Every 4 Months Up to End of Treatment (2 years) | 
| Time to Death |  | Up to End of Treatment (2 years) | 
| Number of Participants with Ventilatory Support |  | Up to End of Treatment (2 years) |